Provera

Basic Provera Information

• INN (International Nonproprietary Name): Medroxyprogesterone acetate.
• Brand Names Available In United Kingdom: Provera and generics; injectable preparations marketed globally as Depo‑Provera and Depo‑SubQ Provera 104 (local UK brand registrations not specified).
• ATC Code: G03DA02.
• Forms & Dosages: Oral tablets 2.5 mg, 5 mg, 10 mg; injectables 104 mg (Depo‑SubQ) and 150 mg/mL (Depo‑Provera) for IM/SQ use.
• Manufacturers In United Kingdom: not specified (Pfizer Inc. listed as a primary global supplier in supplied data).
• Registration Status In United Kingdom: not specified in supplied data; Provera is approved by multiple national regulators in reviewed markets.
• OTC / Rx Classification: Prescription only (Rx) in reviewed markets.

Critical Warnings And Restrictions (Safety First)

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Are you pregnant or might be pregnant? Confirm pregnancy status before starting Provera because medroxyprogesterone acetate is contraindicated in pregnancy.

Medroxyprogesterone acetate is contraindicated in patients with active or prior thromboembolic disease, known or suspected breast or genital malignancy, undiagnosed vaginal bleeding, and significant liver dysfunction.

Elderly patients need extra caution because of increased thromboembolic and cognitive risks and because routine dose reduction is not recommended.

People with chronic illness — for example diabetes with vascular complications, uncontrolled hypertension, epilepsy or severe migraine — should have specialist review and documented informed consent before starting Provera.

• Use this clinic checklist before prescribing: pregnancy test, VTE risk assessment, breast/genital examination as indicated, review of liver function, medication reconciliation, mental‑health screen.

A quick‑reference table (contraindications vs monitoring actions) is recommended in clinic notes for rapid checks.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Some people experience side effects that can impair concentration or alertness such as drowsiness, dizziness or marked mood changes.

If a patient reports drowsiness, dizziness or impaired concentration after taking Provera they must not drive, operate heavy machinery, or carry out safety‑critical work until these symptoms resolve.

Advise patients to follow the Highway Code and their workplace safety rules, and record the safety advice in the clinical notes.

Q&A — “Can I Drive After Taking It In The UK?”

Short answer: Usually yes, but if you feel drowsy, dizzy or impaired you must not drive.

Follow the UK Highway Code and workplace safety rules and document the advice in patient records.

Usage Basics

INN, Brand Names Available In The United Kingdom

What is Provera? The International Nonproprietary Name (INN) is medroxyprogesterone acetate.

Common global brands include Provera for oral use and Depo‑Provera/Depo‑SubQ Provera for injectable contraception.

INN → medroxyprogesterone acetate.

Oral Brand → Provera.

Injectable Brands → Depo‑Provera, Depo‑SubQ Provera 104.

Legal Classification (POM, P, GSL)

Provera and injectable medroxyprogesterone acetate are prescription‑only medicines across reviewed markets.

In the UK context supply and use must follow national licensing and prescribing frameworks and a valid prescription is required for dispensing.

Electronic prescribing and NHS repeat dispensing are commonly used in primary care for contraception and HRT medicines.

Dosing Guide

Standard Regimens (NHS Guidelines)

Typical oral regimens for secondary amenorrhoea or abnormal uterine bleeding are 5–10 mg daily for 5–10 days, often started around day 16–21 of the cycle.

For endometrial protection when oestrogen is prescribed, oral medroxyprogesterone acetate is commonly given 5–10 mg daily for 12–14 consecutive days each month.

Injectable contraceptive regimens are Depo‑Provera 150 mg IM every 12 weeks and Depo‑SubQ Provera 104 mg SQ every 12 weeks.

Adjustments For Comorbidities

There is no routine elderly dose reduction but assess thromboembolic and cognitive risk before prescribing.

Avoid use in significant liver impairment because medroxyprogesterone acetate is hepatically metabolised and contraindicated in severe liver disease.

Children are not routinely indicated and any use should be specialist‑guided and individually dosed.

For prolonged injectable use beyond two years monitor mood, weight, blood pressure and discuss bone health and DEXA scanning where risk factors are present.

Q&A — “What If I Miss A Dose?”

Oral tablet: take the missed dose as soon as remembered on the same day; if it is near the time for the next dose skip the missed dose — do not double up.

Injectable: attend for the injection as soon as possible and use backup contraception if the injection is delayed beyond the recommended window.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

There are no major food interactions documented with medroxyprogesterone acetate tablets or depot injections.

Alcohol can worsen mood changes and headache and should be limited if patients experience these side effects.

Maintain a healthy diet and consider calcium and vitamin D supplementation if using depot injections long‑term because of bone density considerations.

• Alcohol caution — may worsen mood/headache and contribute to weight gain.
• Smoking — increases overall cardiovascular risk and compounds VTE concerns.
• Nutrition — adequate calcium and vitamin D advised for long‑term depot users.
• Caffeine — may exacerbate anxiety or headache in susceptible individuals.

Common Drug Conflicts (MHRA Yellow Card Data)

Hepatic enzyme inducers such as carbamazepine, rifampicin and some antiretrovirals can reduce progestogen levels and may affect efficacy.

Concurrent central nervous system depressants or sedating antidepressants can increase drowsiness or dizziness when combined with progestogens.

Always perform medication reconciliation at every visit and report suspected adverse reactions via the MHRA Yellow Card scheme.

• Review anticonvulsants, HIV medicines and rifampicin.
• Ask about herbal remedies such as St John’s wort which can induce hepatic enzymes.
• Check anticoagulants and antidepressants for interaction potential and adjust monitoring accordingly.

User Reports & Trends

What do patients say online? NHS information pages, Patient.info and parenting forums commonly report themes of menstrual change, weight concerns and mood effects with Provera or depot contraception.

Forums and reviews show mixed views on injectable contraception: many praise convenience and reliable contraception while others report concern about delayed return of fertility and mood changes.

• Positive themes: effective bleeding control and convenience of injections.
• Negative themes: mood changes, perceived weight gain, and concern about delayed fertility after long‑acting injectables.
• Service access: growing use of online pharmacies for repeat prescriptions and concerns about continuity of care and counselling quality.

Note: forum and review data are anecdotal and should be cross‑checked with clinical evidence and MHRA or NHS guidance.

Access & Purchase Options (United Kingdom)

High‑Street Pharmacies & Clinics

NHS GPs and sexual health clinics provide prescriptions and injectable contraception services for Provera and depot formulations where indicated.

Large pharmacy chains provide dispensing services for valid prescriptions and clinics commonly administer injectable Depo formulations.

• Patient checklist: book GP or contraception appointment, disclose VTE history, bring a current medication list, expect counselling on risks and benefits.

Online Pharmacies And NHS E‑Prescriptions

The NHS Electronic Prescription Service (EPS) allows prescriptions to be sent electronically to a nominated pharmacy for convenient collection.

Reputable online pharmacies must be registered with the General Pharmaceutical Council and require a valid prescription before supplying prescription medicines.

In our online pharmacy, provera is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Mechanism & Pharmacology

Simplified Explanation

Medroxyprogesterone acetate is a synthetic progestogen that acts on progesterone receptors to stabilise the endometrium and reduce uterine bleeding.

Depot injections additionally suppress ovulation, providing a reliable contraceptive effect for about three months per dose.

ATC code is G03DA02 and the classification is progestogens.

Clinical Terms

Progestogen → a synthetic progesterone‑like hormone.

Depot → a long‑acting injectable formulation that releases drug over time.

Amenorrhoea → absence of menstrual periods.

Medroxyprogesterone acetate undergoes hepatic metabolism and the half‑life varies by formulation, with depot forms providing sustained systemic exposure.

Because of hepatic metabolism, interactions with enzyme inducers are clinically relevant and liver disease is a contraindication.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Authorised uses include treatment of abnormal uterine bleeding and secondary amenorrhoea, endometrial protection when combined with oestrogen in HRT, and contraceptive use via depot injections.

Standard dosages per indication are oral 5–10 mg for bleeding/amenorrhoea and depot injections 150 mg IM or 104 mg SQ every three months for contraception.

Off‑Label Practices In NHS And Private Care

Off‑label use can include period delay in specific circumstances or symptom control in endometriosis, but such uses require documented rationale and informed consent.

• Clinician checklist for off‑label use: state clinical reason, review alternatives, document informed consent, and set a monitoring plan.

Key Clinical Findings (UK/EU Studies)

Recent evidence reviews confirm medroxyprogesterone acetate is effective for controlling dysfunctional uterine bleeding and for use as endometrial protection in HRT regimens.

Observational data continue to report mood changes and weight gain in some patients, and there are reproducible signals for decreased bone mineral density with long‑term depot use.

Clinicians should consult MHRA safety updates, local formularies and the relevant SmPC for the most current safety signals and prescribing details.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Discuss efficacy for the indication and likely time to effect.
• Review side‑effect profile including mood and weight.
• Assess thrombosis risk and suitability in VTE‑prone patients.
• Consider bone health, particularly with depot contraception used beyond two years.
• Consider the patient’s desire for future fertility — depot injections can delay return to fertility.

Common Questions (Patient FAQs From UK Consultations)

• Will Provera Stop My Period Permanently? — Usually it regulates or induces a withdrawal bleed; long‑term depot contraception can cause amenorrhoea that is generally reversible on cessation.
• Is Fertility Affected Long‑Term? — Fertility usually returns after stopping oral treatment; depot injections may delay return of fertility by several months but are generally reversible.
• Can I Take It With My Antidepressant Or Anticonvulsant? — Check for interactions and medication‑specific issues; specialist review may be needed for enzyme‑inducing anticonvulsants or interacting antidepressants.
• When Should I Seek Urgent Help? — Seek urgent care for signs of DVT/PE, severe chest pain, sudden weakness, jaundice or severe depressive symptoms.

NHS Cost & Access Comparison Table

Create a local table with typical sources and fees because prices change frequently and vary by region.

Patients should confirm local clinic fees for injectable administration and check national prescription exemptions for free or reduced‑cost care.

Registration & Regulation

MHRA Approval Process

Medicines must be licensed with a Summary of Product Characteristics and patient information leaflet and clinicians should consult the SmPC for details on indications and contraindications.

Regulatory status is determined by national agencies and medroxyprogesterone acetate preparations are prescription‑only in reviewed markets.

NHS Prescribing Framework

Prescribers must document the indication, counselling and follow‑up arrangements and local sexual health service protocols usually set pathways for depot contraception administration.

• Documentation checklist: consent, baseline checks, planned follow‑up date, and Yellow Card reporting if an adverse event occurs.

Storage & Handling (United Kingdom Households & Clinics)

Home Storage (Cold/Damp Climate)

Store oral tablets at or below 25–30°C, keep them in the original packaging and protect from damp and children.

Injectable products should be stored at 15–30°C, protected from light and must not be frozen.

Clinical Handling & Transport

Clinics should verify batch and expiry on arrival, store injectables per manufacturer instructions and document lot numbers for pharmacovigilance.

Aseptic technique is required for IM or SQ administration and provide patients with safe disposal advice for sharps if needed.

Expiry Date → the last usable date on the packaging.

Cold Chain → maintenance of required temperatures during transport and storage.

Guidelines For Proper Use (Patient Safety & Pharmacist Counselling)

UK Pharmacist Counselling Style

Open with the patient’s primary concern and confirm the indication for Provera before counselling.

Review contraindications — especially VTE history, breast cancer and liver disease — and check concurrent medicines for interactions such as enzyme inducers or CNS depressants.

Explain common side effects including menstrual changes, possible weight change and mood alterations and advise on driving and work safety if drowsiness occurs.

• Counselling checklist: indication, contraindications, medicine review, side effects, follow‑up plan and documentation per GPhC standards.

NHS Patient Safety Advice

Advise patients when to seek urgent care: symptoms of DVT/PE, severe chest pain, sudden neurological changes, jaundice or severe depression.

Routine follow‑up should include blood pressure, weight and mood assessment at three months and annually for long‑term use.

Discuss bone health if depot contraception is to be used for more than two years and consider DEXA scanning when other risk factors are present.

Encourage reporting of suspected adverse reactions via the MHRA Yellow Card scheme and follow local care pathways for switching treatments.

Delivery Across United Kingdom